BTIG Research Issues Pessimistic Forecast for Humacyte (NASDAQ:HUMA) Stock Price

Humacyte (NASDAQ:HUMA) had its price objective decreased by stock analysts at BTIG Research from $3.00 to $2.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s target price points to a potential upside of 74.67% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 11th. Benchmark lowered their target price on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 21st. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Tuesday, April 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research note on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.57.

Humacyte Price Performance

NASDAQ:HUMA traded up $0.24 on Wednesday, hitting $1.15. The company had a trading volume of 19,093,454 shares, compared to its average volume of 6,415,261. The stock has a market capitalization of $254.21 million, a price-to-earnings ratio of -5.73 and a beta of 2.31. The company has a current ratio of 3.69, a quick ratio of 2.95 and a debt-to-equity ratio of 20.08. The firm has a 50 day moving average of $0.86 and a two-hundred day moving average of $1.07. Humacyte has a 52 week low of $0.55 and a 52 week high of $2.93.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%. On average, research analysts anticipate that Humacyte will post -0.39 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. R Squared Ltd grew its holdings in shares of Humacyte by 140.5% during the first quarter. R Squared Ltd now owns 62,911 shares of the company’s stock valued at $38,000 after buying an additional 36,758 shares during the last quarter. Private Advisor Group LLC boosted its holdings in Humacyte by 48.3% during the first quarter. Private Advisor Group LLC now owns 832,799 shares of the company’s stock worth $505,000 after purchasing an additional 271,222 shares during the last quarter. Wealth Effects LLC boosted its holdings in Humacyte by 33.6% during the first quarter. Wealth Effects LLC now owns 204,500 shares of the company’s stock worth $124,000 after purchasing an additional 51,433 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Humacyte by 841.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock worth $68,000 after purchasing an additional 62,931 shares during the last quarter. Finally, Aristides Capital LLC purchased a new position in Humacyte during the fourth quarter worth about $156,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.